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Abstract
Objectives. To describe and compare the occurrence of newly diagnosed uveitis in children with JIA receiving MTX,
etanercept, adalimumab and infliximab.
Methods. This on-drug analysis included patients within UK JIA registries (British Society for Paediatric and Adolescent
Rheumatology Etanercept Cohort Study and Biologics for Children with Rheumatic Diseases) with non-systemic disease,
registered at MTX or biologic start with no history of uveitis. Follow-up began from date of first treatment, continuing until
first uveitis, discontinuation of registered drug, most recent follow-up up or death, whichever came first. Hazard ratios
comparing risk of uveitis between drugs were calculated using propensity-adjusted Cox regression.
Results. A total of 2294 patients were included (943 MTX, 304 adalimumab/infliximab, 1047 etanercept). There were 44
reported cases of uveitis (27 MTX, 16 etanercept, 1 adalimumab). Unadjusted hazard ratio showed a reduced risk of
uveitis in biologic cohorts compared with MTX. After adjusting for propensity deciles, there was no significant difference
in the risk of uveitis between patients receiving etanercept or MTX [hazard ratio 0.5 (0.21.1)]. Fully adjusted comparisons
were not possible for adalimumab/infliximab as there were too few events.
Conclusions. In this first paper to compare the rate of new onset uveitis across the three main anti-TNF therapies used
in JIA, a new diagnosis of uveitis is less common among patients starting biologics compared with MTX, although this did
not reach statistical significance. The suggested protective effect of etanercept is likely explained by confounding,
whereby patients in the MTX cohort are younger and earlier in disease, and therefore at greater risk of developing uveitis
compared with etanercept patients.
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Rheumatology key messages
. This is the first study comparing uveitis risk within each of the anti-TNF therapies.
. New diagnosis of uveitis is less common in JIA patients starting etanercept compared with MTX.
. The suggested protective effect of etanercept is likely explained by the influence of age and disease duration.
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Introduction
JIA is the most common inflammatory rheumatic disease
in childhood, thought to affect around 4 in 1000 children
[1, 2]. Uveitis is a significant comorbidity associated with
JIA, with prevalence reported between 12 and 30% [3]. It
is characterized by inflammation of the middle layer of the
eye, and can result in significant visual morbidity [4], sug-
gesting that diagnoses and treatment should be a priority.
There are a number of widely accepted risk factors for
the development of JIA-associated uveitis, which include
younger age at onset of JIA (<7 years) and the presence of
ANAs [3]. There have also been reports of uveitis occur-
ring more frequently in patients with oligoarticular JIA
compared with polyarticular JIA, and in female patients
[5, 6]. Uveitis is also thought to occur early in the JIA dis-
ease course, with a German study reporting that 73% of
406 patients who developed uveitis did so within the first
year following JIA diagnosis [6].
In addition to these demographic and clinical factors,
etanercept, a common TNF inhibitor treatment for JIA,
has been considered as a potential risk factor in the devel-
opment of uveitis in a cohort of patients with RA [7]. Within
JIA, there has been a concern that etanercept can increase
the likelihood of recurrence of uveitis in patients with a pre-
existing history of the disease [1, 8], with one study sug-
gesting that this was more common when patients were
receiving etanercept monotherapy compared with etaner-
cept and MTX in combination [9]. A randomized controlled
trial exploring the role of etanercept as a treatment for uve-
itis found no difference in outcome between etanercept
and placebo-treated patients [10], suggesting that among
children with uveitis, etanercept is not an effective treat-
ment, unlike other drugs within the TNF inhibitor class,
including adalimumab via a randomized controlled trial
(SYCAMORE) [11] and infliximab through a case series
[12]. Whether or not etanercept is associated with an
increased risk of developing new onset uveitis in patients
with JIA is less clear. Similarly, although adalimumab and
infliximab are effective treatments for many children with
uveitis it is not known whether use of these drugs can pre-
vent the onset of uveitis.
The aims of the present study are therefore to describe
and compare the occurrence of newly diagnosed uveitis in
children with JIA receiving MTX, etanercept, adalimumab
and infliximab who do not have a history of uveitis at the
start of therapy.
Methods
Patients
Patients recruited to one of two UK JIA national prospect-
ive treatment registries were included [the British Society
for Paediatric and Adolescent Rheumatology Etanercept
Cohort Study (BSPAR-ETN) established in 2004 and the
Biologics for Children with Rheumatic Diseases (BCRD)
study established in 2010]. To be enrolled in the studies,
patients were required to have a diagnosis of JIA, classified
according to the ILAR criteria [13]. A detailed explanation of
the study methods of both studies has been described
previously [14]. Patients starting etanercept (BSPAR-ETN)
or a non-etanercept biologic (BCRD) for JIA are ap-
proached to join the respective studies alongside children
starting MTX, who form a comparison cohort within the
studies. Recruitment is recommended but not mandatory.
Data are captured in identical manners regardless of which
drug is started and which study the child is enrolled in. Both
studies received ethical approval from a National Health
Service Ethics Committee and written informed consent
from parents (and where appropriate patients) was pro-
vided in accordance with the Declaration of Helsinki.
Data collection and follow-up
Baseline data (defined as at the time of starting a biologic
or MTX) were collected by the paediatric rheumatologist
or clinical research nurse using a web-based question-
naire. Data collected include demographics (age,
gender), disease status [disease duration, active joint
count, limited joint count, ESR, CRP, physician global as-
sessment, patient/parent global assessment, pain visual
analogue scale, Childhood Health Assessment
Questionnaire (CHAQ) [15], juvenile arthritis disease activ-
ity score-71] [16], ILAR disease classification, drug history
and comorbidities. It is also recorded whether or not the
patient has a history of uveitis at study registration and
whether it was active at the time of registered drug start.
ANA status was not collected over the period of patient
recruitment included in this analysis. Follow-up data were
extracted from the medical record at 6 months, 12 months
and annually thereafter, and included current treatments
and changes to anti-rheumatic therapy, as well as occur-
rence of serious and non-serious adverse events, includ-
ing uveitis.
All adverse events are reported verbatim by the hos-
pitals and coded centrally using the Medical Dictionary
for Regulatory Activities [17].
Newly diagnosed uveitis cases were defined as any re-
ported adverse event of uveitis in patients that had no
previous history of uveitis recorded at baseline. Events
coded to the Medical Dictionary for Regulatory Activities
preferred terms ‘uveitis’ or ‘iridocyclitis’ (known as anter-
ior uveitis) were included in the analysis. Additional infor-
mation using a standardized proforma, including location
and type of uveitis, was requested in all cases to verify the
event as a new case of uveitis (vs a flare). Only first diag-
noses of uveitis were included in our analysis.
Statistical analysis
The analysis included all children with non-systemic JIA
registered at the point of starting MTX, etanercept, adali-
mumab or infliximab who did not have a history of uveitis
at the start of the registered drug. For the purpose of ana-
lysis, children starting adalimumab and infliximab were
combined as numbers in each individual drug cohort
were small. For all patients, person-years of exposure
began from date of first treatment with the respective
drug and continued until first diagnosis of uveitis, most
recent study follow-up recorded up to 30 June 2018,
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discontinuation of registered drug or death, whichever
came first. Events were only included if patients were
receiving their treatment of interest (biologic or MTX) at
the time of or within the 90 days preceding their first diag-
nosis of uveitis, to allow for any lag effect.
Patients who registered on MTX and later switched to
etanercept or another biologic were followed in the MTX
cohort until the point of biologic start. At this point they
were censored from the MTX cohort and subsequently
followed in the etanercept or adalimumab/infliximab
cohort as described above. Similarly, patients who
switched between biologics were followed in one cohort
until the point of switch, from which point they were cen-
sored from the first cohort and followed up in the second
cohort.
Baseline comparisons between cohorts are shown,
using non-parametric descriptive statistics. Crude rates of
uveitis are presented per 100 person-years with 95% CIs.
Cox proportional hazard models were used to compare
rates of newly diagnosed uveitis between the MTX and
etanercept cohorts across all exposure time. Due to a
lack of events, only unadjusted hazard ratios (HRs) are pre-
sented comparing MTX and adalimumab/infliximab or be-
tween etanercept and adalimumab/infliximab. Sensitivity
analyses included (i) patients diagnosed with JIA under
the age of 12 years (all follow-up included) and (ii) patients
diagnosed with JIA under the age of 12 years with follow-
up censored at 12th birthday. Current UK JIA uveitis
screening guidelines suggest more frequent screening in
patients younger than 12 years(3), therefore the latter two
analyses were conducted to rule out any bias caused by
this screening effect.
In order to reduce any effects of selection bias, a series
of propensity scores stratified into deciles were used to
adjust for potential confounding effects of baseline differ-
ences between the cohorts (etanercept vs MTX, etaner-
cept-combination vs MTX, etanercept-monotherapy vs
MTX and etanercept-combination vs etanercept-monother-
apy) and included age, sex, disease severity (using base-
line CHAQ and juvenile arthritis disease activity score-71),
disease duration, baseline oral steroid use, ethnicity (white
vs non-white) and ILAR category (Supplementary Table S1,
available at Rheumatology online). The reported bias be-
tween the cohorts was low at between 1.5 and 5%. Two
time-varying covariates were also included to estimate the
probability of an etanercept-combination patient becoming
an etanercept-monotherapy patient, and an etanercept-
monotherapy patient becoming an etanercept-combination
patient. These were included as covariates in the etaner-
cept-combination vs etanercept-monotherapy model.
Finally, a series of univariable Cox regressions were per-
formed on baseline variables to identify possible risk fac-
tors in the development of new onset uveitis within the
whole cohort.
All analyses were performed using Stata, version 14
(StataCorp, 2015, Stata Statistical Software: Release 14,
College Station, TX, USA: StataCorp LP). Missing data
were accounted for using multiple imputation (20 imput-
ations), using the ice package in Stata [18]. As well as
including baseline co-variates in the imputation model,
uveitis incidence (quantified as whether a patient ever de-
veloped new onset uveitis) and log time to first uveitis
were also included.
Results
A total of 2698 patients with non-systemic JIA were recruited
at point of starting one of the study drugs (1038 MTX, 540
adalimumab/infliximab, 1120 etanercept). Of these, 95 (9%),
236 (44%) and 73 (7%), respectively, had a history of uveitis
at registration and were excluded from further analysis, re-
sulting in a total of 2294 patients in the analysis; 943 MTX,
1047 etanercept and 304 adalimumab/infliximab. Patients in
the final adalimumab/infliximab cohort consisted of 243
(80%) starting adalimumab and 61 (20%) starting infliximab.
Baseline characteristics are presented in Table 1. The co-
horts were relatively similar with respect to age and gender,
but patients starting MTX were slightly younger and had
much shorter disease duration compared with those starting
biologics (median 2 years for both etanercept and adalimu-
mab/infliximab vs 0 years for MTX). Patients starting MTX
were more likely to have persistent oligoarthritis and patients
starting adalimumab or infliximab were more likely to have
enthesitis-related arthritis.
Risk of new onset uveitis
There were 44 new diagnoses of uveitis over a total of
5456 person-years of follow-up: 27 in patients on MTX,
16 in patients on etanercept (etanercept-combination =
11, etanercept-monotherapy = 5) and 1 in a patient on
adalimumab (Table 2). The majority of cases were unilat-
eral at diagnosis with most children being diagnosed with
anterior uveitis. There were no cases of panuveitis re-
ported within this study. Cases were seen most frequently
in those patients with oligoarticular or RF-negative poly-
arthritis (Table 3). Crude incidence rates, presented per
100 person-years, were 1.6 (95% CI 1.0, 2.3) in patients
taking MTX, 0.6 (95% CI 0.3, 0.9) in those receiving eta-
nercept and 0.1 (95% CI 0, 0.4) in patients receiving ada-
limumab or infliximab. The incidence rate was higher in
patients in the etanercept-combination when compared
with etanercept-monotherapy cohort.
The mean age at uveitis diagnosis was 7 years in the
etanercept cohort vs 4 years in the MTX cohort, with time
from JIA diagnosis to uveitis onset 4 and 2 years, respect-
ively. The adalimumab patient was over 15 years of age at
the time of uveitis diagnosis and this occurred 2 years
post-JIA diagnosis. Unadjusted HR showed a reduced
risk of uveitis in all etanercept cohorts and the adalimu-
mab/infliximab cohort when compared with patients on
MTX; however, after adjusting for propensity deciles,
there was no significant difference in the risk of uveitis
between patients receiving etanercept or MTX [HR 0.5
(95% CI 0.2, 1.1)]. Although the rates were higher in pa-
tients receiving etanercept in combination with MTX com-
pared with those receiving it as monotherapy, this did not
reach statistical significance [HR 2.6 (95% CI 0.8, 8.8)].
Similar results were found in sensitivity analysis limited
to children with a JIA diagnosis before the 12th birthday
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TABLE 1 Baseline characteristics of the etanercept, adalimumab, infliximab and MTX registered patients
Characteristic
MTX
cohort
ETN
cohort
ADA/INF
cohort
Total missing
data, n (%)
N 943 1047 304 —
Age, median (IQR), years 10 (413) 11 (614) 10 (613) 0
Gender, n (%)
Female 662 (70) 721 (69) 197 (65) 0
Ethnicity, n (%)
White 788 (84) 890 (86) 274 (90) 29 (1)
Disease duration, median (IQR), years 0 (01) 2 (15) 2 (15) 49 (2)
ILAR classification, n (%) 82 (4)
Oligoarthritis: persistent 160 (17) 55 (5) 16 (5)
Oligoarthritis: extended 149 (16) 205 (20) 48 (16)
Polyarthritis: RF-negative 330 (36) 400 (39) 107 (35)
Polyarthritis: RF-positive 81 (9) 122 (12) 39 (13)
PsA 82 (9) 75 (7) 25 (8)
Enthesitis-related arthritis 72 (8) 101 (10) 62 (21)
Undifferentiated arthritis 34 (4) 48 (5) 1 (1)
Active joint count, median (IQR) 5 (29) 5 (29) 3 (16) 183 (8)
Limited joint count, median (IQR) 3 (17) 4 (18) 2 (16) 236 (10)
CHAQ score, median (IQR) 03 0.9 (0.31.5) 1.0 (0.31.6) 0.8 (0.31.4) 815 (36)
Pain VAS, median (IQR) 10 cm 5 (27) 5 (27) 4 (1.36.4) 787 (34)
ESR, median (IQR), mm/h 15 (730) 11 (525) 9 (522) 406 (18)
CRP, median (IQR), mg/l 5 (414) 5 (414) 5 (27) 385 (17)
Physician global assessment, median (IQR), 10 cm 4 (26) 4 (25) 3 (25) 803 (35)
Patient/parent global assessment, median (IQR), 10 cm 4 (26) 4 (26) 4 (16) 733 (32)
JADAS-71, median (IQR) 14 (923) 14 (820) 12 (718) 1233 (54)
Concurrent oral steroid use, n (%) 202 (21) 181 (17) 52 (17) 0
Concurrent MTX use, n (%) — 555 (53) 202 (66) 0
Previous biologic exposure, n (%) — 14 (1) 132 (43) 0
ADA: adalimumab; INF: infliximab; ETN: etanercept; IQR: interquartile range; CHAQ: childhood Health Assessment
Questionnaire; VAS: visual analogue scale; JADAS-71: 71-joint juvenile arthritis disease activity score.
TABLE 2 Crude incidence rates and HRs of new onset uveitis in patients on etanercept or adalimumab/infliximab vs MTX
MTX ETN ADA/INF
ETN
monotherapy
ETNMTX
combination
therapy
Person-years of exposure 1701 2826 929 1707 1120
New diagnosis of uveitis, n 27 16 1 5 11
Crude incidence rates of uveitis
(per 100 person-years)
1.6 (1.02.3) 0.6 (0.30.9) 0.1 (00.4) 0.3 (0.10.7) 1.0 (0.51.8)
Time from JIA diagnosis to uveitis
diagnosis,
median (IQR), years
2 (13) 4 (25) 2 4 (45) 4 (25)
Age at uveitis diagnosis, median (IQR),
years
4 (39) 7 (610) >15 7 (6.57.5) 9 (610)
Unadjusted HR of uveitis diagnosis
(95% CI)*
Ref 0.4 (0.2, 0.7) 0.07 (0.009, 0.5) 0.2 (0.08, 0.6) 0.6 (0.3, 1.3)
— Ref 0.2 (0.02, 1.4) — —
PS-adjusted HR of uveitis diagnosis
(95% CI)a,*
Ref 0.5 (0.2, 1.1) — 0.3 (0.08, 1.0) 0.6 (0.3, 1.6)
— — — Ref 2.6 (0.8, 8.8)
PS-adjusted HR of uveitis diagnosis
(95% CI)a,b,*
Ref 0.5 (0.2, 1.1) — 0.3 (0.07, 0.9) 0.7 (0.3, 1.7)
— — — Ref 2.7 (0.8, 8.9)
PS-adjusted HR of uveitis diagnosis
(95% CI)a,c,*
Ref 0.6 (0.2, 1.4) — 0.4 (0.1, 1.4) 0.7 (0.3, 1.7)
— — — Ref 2.4 (0.7, 8.1)
aFully adjusted using propensity deciles (includes age, gender, CHAQ, JADAS, disease duration, ethnicity, comorbidity, base-
line steroid use and ILAR category). bSensitivity analysis limited to patients younger than 12 years at JIA onset. cSensitivity
analysis limited to patients censored at their 12th birthday. *First line if all TNF drugs compared to MTX, second line is ETN
compared to ADA/INF. ADA: adalimumab; INF: infliximab; ETN: etanercept; IQR: interquartile range; HR: hazard ratio; PS:
propensity decile; CHAQ: childhood Health Assessment Questionnaire; JADAS: juvenile arthritis disease activity score.
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and in an analysis censored at the child’s 12th birthday
(Table 2).
Risk factors in the development of newly diagnosed
uveitis
A univariable analysis of risk factors in the development of
new uveitis (Table 4) found a significant association between
development of uveitis and younger age at baseline, shorter
disease duration, being of non-white ethnicity and having
oligoarticular disease (compared with other ILAR categories
excluding RF-negative polyarthritis). Gender, disease sever-
ity and functional disability were not found to be significantly
associated with development of uveitis in this cohort.
Discussion
Uveitis is accepted to be one of the most common com-
plications of JIA, with a variety of recognized risk factors
such as younger age and oligoarticular subtype [3]. There
is concern that etanercept may flare disease in those with
pre-existing uveitis [1, 8]. As a consequence, etanercept is
rarely the first choice of biologic in patients with JIA with a
history of uveitis. However, the relationship between eta-
nercept and the new development of uveitis in patients
with JIA remains unclear.
From this analysis, which has used data from children and
young people enrolled in national cohort studies of treat-
ments for JIA, no association was found between the use
of etanercept and the occurrence of new uveitis when com-
pared with those receiving MTX for the first time, although
the crude incident rates were lower in patients receiving
etanercept. Concurrent MTX use with etanercept did not
appear to have a further protective effect in this cohort.
Given the low occurrence of events in the adalimumab/inflix-
imab cohort, it is difficult to conclude whether these drugs
had any protective effect over the occurrence of uveitis and
the data should not be used to preferentially treat children
with no history of uveitis with one treatment over another.
The lower rates of uveitis among patients starting etaner-
cept do not support a causative link between etanercept and
TABLE 3 Characteristics of new onset uveitis cases in patients on etanercept or adalimumab/infliximab vs MTX
MTX ETN ADA/INF
ETN
monotherapy
ETNMTX
combination
therapy
New diagnosis of uveitis, n 27 16 1 5 11
New diagnosis of uveitis by ILAR subtype, n
Oligoarthritis: persistent 6 1 0 1 0
Oligoarthritis: extended 5 9 0 3 6
Polyarthritis: RF-negative 13 4 1 0 4
Polyarthritis: RF-positive 1 0 0 0 0
PsA 0 1 0 0 1
Enthesitis-related arthritis 1 1 0 1 0
Undifferentiated arthritis 1 0 0 0 0
Uveitis location, n (%)
Bilateral 9 (33) 6 (38) 0 0 6 (55)
Unilateral 14 (52) 6 (38) 1 (100) 4 (80) 2 (18)
Not stated 4 (15) 4 (24) 0 1 (20) 3 (27)
Uveitis type, n (%)
Anterior 19 (70) 9 (56) 1 (100) 5 (100) 4 (36)
Panuveitis 0 0 0 0 0
Not stated 8 (30) 7 (44) 0 0 7 (64)
ADA: adalimumab; INF: infliximab; ETN: etanercept.
TABLE 4 Univariable predictors of new onset uveitis in all
patients [presented as HR (95% CI)]
Predictor
New onset uveitis
[HR (95% CI)]
Gender
Male Ref
Female 1.7 (0.9, 3.1)
Age at baseline (years) 0.8 (0.7, 0.8)
Disease duration at baseline (years) 0.9 (0.8, 0.9)
Ethnicity
Non-white Ref
White 0.5 (0.3, 0.8)
ILAR subtype
Other subtype Ref
Oligoarthritis 2.5 (1.3, 4.9)
RF-negative polyarthritis 1.4 (0.7, 2.9)
Oral CS use at baseline 1.3 (0.7, 2.3)
CHAQ at baseline 1.2 (0.9, 1.7)
JADAS-71 at baseline 1.0 (0.9, 1.0)
HR: hazard ratio; CHAQ: childhood Health Assessment
Questionnaire; JADAS-71: 71-joint juvenile arthritis disease
activity score.
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the development of uveitis. However, it should be noted that
the patients in the MTX and etanercept cohorts differed sig-
nificantly with respect to their baseline risk of uveitis. Patients
starting MTX did so early in disease course and were also
more likely to have oligoarthritis. Subsequently, they also de-
veloped their uveitis at a younger age (median 4 vs 7 years).
Younger age (<7years) is an accepted risk factor in the de-
velopment of uveitis [5] and may explain in part the difference
in crude rates observed between etanercept- and MTX-trea-
ted patients. Thus, by the time patients with JIA start etaner-
cept, they may be inherently at a lower overall risk of
developing uveitis, a so-called ‘healthy user’ effect, which
may be more prominent in the ‘older’ etanercept cohort
who are further along in their disease course, consistent
with recent findings that uveitis is most common in the first
year of disease [6]. It is also possible that a further selection
bias occurred with regard to choice of first biologic in more
recent years. As knowledge about a possible association
between etanercept and uveitis became more widespread,
patients who were perceived by their treating paediatric
rheumatologist as having a higher risk of developing uveitis,
such as those who were younger, ANA positive or had an
oligoarticular subtype, might have been steered away from
etanercept treatment towards an alternative biologic.
Unfortunately information on ANA was not captured in this
study at the time of recruitment of patients included in this
analysis, but no significant different in age between patients
starting adalimumab/infliximab or etanercept was observed.
The main strengths of the study are related to the size of
the cohorts, with close to 2300 patients included in this
study, the detailed follow-up procedures used and the
prospective study design minimizing potential recall
bias. Furthermore, extensive uveitis information is cap-
tured from centres using specially designed proformas,
which ask for the type, localization and course of uveitis,
as well as establishing whether it is a new or recurrent
event. This minimizes the risk of events being misclassi-
fied as new if in fact the patient has had uveitis previously.
As a non-randomized observational treatment study,
the study is subject to the limitations common to all
such research. Despite the overall large sample size, the
size of the cohort of children starting adalimumab or inflix-
imab who did not already have uveitis was relatively low.
There were also missing data across all covariates, al-
though there was not a complete lack of information for
any patient and therefore, multiple imputation was used to
account for these missing covariate data.
In conclusion, this study found that a new diagnosis of
uveitis is less common among patients with JIA starting
etanercept compared with MTX, although this did not
reach statistical significance. The suggested protective
effect of etanercept is likely explained by the influence
of age and disease duration, whereby patients in the
MTX cohort are, on average, younger and so more ‘at
risk’ of developing uveitis compared with etanercept pa-
tients. As a consequence, and in the absence of a suffi-
cient comparison group, our understanding of what
additional risk etanercept adds when looking at the risk
of developing uveitis remains unclear.
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